中华肝脏外科手术学电子杂志
中華肝髒外科手術學電子雜誌
중화간장외과수술학전자잡지
Chinese Journal of Hepatic Surgery
2015年
5期
297-300
,共4页
刘瑞磊%张鹏%张艳玲%许尔蛟%汤谧%张翘楚%李玺%Department of Thyroid Breast Surgery
劉瑞磊%張鵬%張豔玲%許爾蛟%湯謐%張翹楚%李璽%Department of Thyroid Breast Surgery
류서뢰%장붕%장염령%허이교%탕밀%장교초%리새%Department of Thyroid Breast Surgery
导管消融术%乳腺肿瘤%肿瘤转移%化学疗法,辅助%肝切除术
導管消融術%乳腺腫瘤%腫瘤轉移%化學療法,輔助%肝切除術
도관소융술%유선종류%종류전이%화학요법,보조%간절제술
Catheter ablation%Breast neoplasms%Neoplasm metastasis%Chemotherapy,adjuvant%Hepatectomy
目的:评价射频消融和手术切除治疗乳腺癌肝转移的疗效。方法回顾性分析2010年1月至2014年5月在中山大学附属第三医院收治的15例乳腺癌肝转移患者临床资料。患者均为女性,年龄33~66岁,中位年龄49岁。所有患者均签署知情同意书,符合医学伦理学规定。根据不同治疗方案将患者分为射频消融+化疗组(消融组,9例)和手术+化疗组(手术组,6例)。观察两组围手术期情况并进行生存分析。围手术期观察数据比较采用t检验,率的比较采用Fisher确切概率法。生存分析采用Kaplan-Meier法和 Log-rank检验。结果消融组平均手术时间为(26±5) min,明显短于手术组的(151±27) min(t=-18.69,P<0.05)。消融组无术中输血情况,手术组术中输血3例。手术组肿瘤清除率为100%,消融组可获得与手术组一致的肿瘤清除率。消融组术后住院时间为(6±2)d,明显短于手术组的(11±5)d(t=-3.70,P<0.05)。消融组术后并发症发生率为4/9,明显低于手术组的5/6(P=0.02)。消融组和手术组的中位生存时间分别为33、23个月。消融组1、2、5年累积生存率分别为88.9%、66.7%、22.2%,手术组分别为82.3%、50.0%、0,两组比较差异无统计学意义(χ2=1.53, P>0.05)。结论乳腺癌肝转移患者采用射频消融治疗可获得与手术切除治疗相同的疗效,且具有手术时间短、术后并发症发生率低、术后住院时间短的优势。
目的:評價射頻消融和手術切除治療乳腺癌肝轉移的療效。方法迴顧性分析2010年1月至2014年5月在中山大學附屬第三醫院收治的15例乳腺癌肝轉移患者臨床資料。患者均為女性,年齡33~66歲,中位年齡49歲。所有患者均籤署知情同意書,符閤醫學倫理學規定。根據不同治療方案將患者分為射頻消融+化療組(消融組,9例)和手術+化療組(手術組,6例)。觀察兩組圍手術期情況併進行生存分析。圍手術期觀察數據比較採用t檢驗,率的比較採用Fisher確切概率法。生存分析採用Kaplan-Meier法和 Log-rank檢驗。結果消融組平均手術時間為(26±5) min,明顯短于手術組的(151±27) min(t=-18.69,P<0.05)。消融組無術中輸血情況,手術組術中輸血3例。手術組腫瘤清除率為100%,消融組可穫得與手術組一緻的腫瘤清除率。消融組術後住院時間為(6±2)d,明顯短于手術組的(11±5)d(t=-3.70,P<0.05)。消融組術後併髮癥髮生率為4/9,明顯低于手術組的5/6(P=0.02)。消融組和手術組的中位生存時間分彆為33、23箇月。消融組1、2、5年纍積生存率分彆為88.9%、66.7%、22.2%,手術組分彆為82.3%、50.0%、0,兩組比較差異無統計學意義(χ2=1.53, P>0.05)。結論乳腺癌肝轉移患者採用射頻消融治療可穫得與手術切除治療相同的療效,且具有手術時間短、術後併髮癥髮生率低、術後住院時間短的優勢。
목적:평개사빈소융화수술절제치료유선암간전이적료효。방법회고성분석2010년1월지2014년5월재중산대학부속제삼의원수치적15례유선암간전이환자림상자료。환자균위녀성,년령33~66세,중위년령49세。소유환자균첨서지정동의서,부합의학윤리학규정。근거불동치료방안장환자분위사빈소융+화료조(소융조,9례)화수술+화료조(수술조,6례)。관찰량조위수술기정황병진행생존분석。위수술기관찰수거비교채용t검험,솔적비교채용Fisher학절개솔법。생존분석채용Kaplan-Meier법화 Log-rank검험。결과소융조평균수술시간위(26±5) min,명현단우수술조적(151±27) min(t=-18.69,P<0.05)。소융조무술중수혈정황,수술조술중수혈3례。수술조종류청제솔위100%,소융조가획득여수술조일치적종류청제솔。소융조술후주원시간위(6±2)d,명현단우수술조적(11±5)d(t=-3.70,P<0.05)。소융조술후병발증발생솔위4/9,명현저우수술조적5/6(P=0.02)。소융조화수술조적중위생존시간분별위33、23개월。소융조1、2、5년루적생존솔분별위88.9%、66.7%、22.2%,수술조분별위82.3%、50.0%、0,량조비교차이무통계학의의(χ2=1.53, P>0.05)。결론유선암간전이환자채용사빈소융치료가획득여수술절제치료상동적료효,차구유수술시간단、술후병발증발생솔저、술후주원시간단적우세。
ObjectiveTo evaluate the therapeutic effects of radiofrequency ablation and surgical resection for liver metastasis from breast cancer.MethodsClinical data of 15 patients with liver metastasis from breast cancer admitted and treated in the Third Affiliated Hospital of Sun Yat-sen University between January 2010 and May 2014 were retrospectively studied. All patients were females with the age ranging from 33 to 66 years old and the median of 49 years old. The informed consents of all patients were obtained and the local ethical committee approval had been received. According to the different therapeutic regimen, the patients were divided into radiofrequency ablation + chemotherapy group (ablation group,n=9) and surgery +chemotherapy group (surgery group,n=6). The conditions of two groups during the perioperative period were observed and the survival analysis was performed. The observations during perioperative period between two groups was compared usingt test, the rates was compared using Fisher's exact test and the survival analysis was conducted using Kaplan-Meier method and Log-rank test.ResultsThe mean operation time of the ablation group was (26±5) min, which was significantly shorter than (151±27) min of the surgery group (t=-18.69,P<0.05). No case in the ablation group received blood transfusion while 3 cases in the surgery group received blood transfusion during the operation. The tumor clearance rate of the surgery group was 100%,which was the same with that of the ablation group. The postoperative hospital stay of the ablation group was (6±2) d, which was signiifcantly shorter than (11±5) d of the surgery group (t=-3.70,P<0.05). The incidence of postoperative complications of the ablation group was 4/9, which was signiifcantly lower than 5/6 of the surgery group (P=0.02). The median survival time of the ablation group and the surgery group was respectively 33, 23 months. The 1-, 2- and 5-year cumulative survival rate were respectively 88.9%, 66.7% and 22.2% for the ablation group and were respectively 82.3%, 50.0% and 0 for the surgery group and no significant difference was observed between two groups (χ2=1.53,P>0.05).ConclusionsThe radiofrequency ablation for patients with liver metastasis from breast cancer can have the same therapeutic effect with surgical resection, and has advantages of short operation time, low incidence of postoperative complications and short postoperative hospital stay.